Skip to content
thestock.space

As of 6 Nov 2026, Sudeep Pharma trades at 69.9× trailing earnings, above the industry P/E of 28.7×, and the shares are 14% below their 52-week high. Sales and net profit grew 14% and 41% a year over 3 years; its ROCE of 24% is the highest among the 7 largest Drug Manufacturers (Specialty & Generic) peers. Debt is 0.19× equity, and its dividend yield is 0.1%. It is a small-cap company with a market cap of ₹13,309 Cr, ranked 31st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 52% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year
Open
₹1,197.10
Day high
₹1,197.10
Day low
₹1,143.70
Prev. close
₹1,190.30
Volume
2.5 L

Health check

3 good · 1 fair · 2 to check
  • ReturnsAhead

    +52.2% over a year, better than 6 of 7 peers.

  • Price tagPricier

    P/E 69.9 vs industry 28.7.

  • GrowthStrong

    Sales +14.4%, profit +40.5% a year over 3 years.

  • ProfitabilityStrong

    ROCE 24.0% vs peer median 17.9%.

  • Balance sheetFair

    Debt 0.19× equity, interest covered 42.9×, Piotroski 4 of 9.

  • Red flags1 to check

    P/E of 69.9 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹13,309 Cr, #31 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Sep 2026: sales ₹710 Cr · profit ₹188 Cr
Market cap
₹13,309 Cr
Small cap
P/E
69.9
Industry 28.7
Price to book
13.80
Peers 4.99
Dividend yield
0.13%
ROE
22.0%
Peers 14.7%
ROCE
24.0%
Peers 17.9%
Debt to equity
0.19
Debt ₹189 Cr
EPS (TTM)
₹16.85
Face value ₹1
OPM (TTM)
35.3%
Net margin 26.5%
Sales growth
+20.9%
Latest quarter vs a year ago
Profit growth
+12.5%
Latest quarter vs a year ago
Price to sales
18.75
EV/EBITDA 53.3

Strengths and risks

Strengths

  • Return on equity of 22.0%.
  • Return on capital employed of 24.0%.
  • Quarterly sales up 20.9% on a year ago.
  • Net margin of 26.5%.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • P/E of 69.9 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Sudeep Pharma

Sudeep Pharma Limited manufactures and sells excipients and specialty ingredients for the pharmaceutical, food, and nutrition industries in India, the United States, and internationally. The company provides mineral salts, such as iron, calcium, sodium, zinc, copper, magnesium, manganese, potassium, picolinates, simethicone, and others;It also offers micronutrient premixes and liposomal, encapsulated ingredients, spray-dried formats, granulated…

Headquarters
Vadodara
Employees
525
Sector
Healthcare
ISIN
INE0QPI01025
Website
sudeeppharma.com

Price range

52 weeks

₹524.05₹1,378.00

Today

₹1,143.70₹1,197.10
Avg volume (3M)
2.8 L
1-year return
plus 52.2%
From 52-week high
minus 14.5%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
SUDEEPPHRMSudeep Pharma1,178.30minus 1.01%13,30969.913.8024.0%22.0%35.3%14.4%40.5%0.13%plus 52.2%
Median of 7 peers–0.51%1,26,43340.94.9917.9%14.7%28.2%11.0%11.5%0.58%22.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrJun 25Sep 25Dec 25Mar 26Jun 26Sep 26
–163172182158197
–107112120103123
–55.56062.654.973.2
–34.1%34.8%34.3%34.7%37.2%
–10.26.86.45.46
–2.31.22.42.12.8
–3.83.93.945.4
−0.1–––––
–59.561.862.754.371
–21.4%22.8%22.6%25.2%27.1%
–45.747.548.940.651.5
2.734.054.29–3.594.59

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+14.4%
Profit CAGR 3Y
+40.5%
EPS CAGR 3Y
+41.1%
ROE
22.0%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
426455497639
–+6.7%+9.4%+28.4%
334271306416
91.8183192223
21.6%40.3%38.5%34.9%
63.76.925.3
3.43.14.75.4
7.9910.614.8
−0.50−0.3−0.2
86175183228
27.5%23.8%24.1%23.6%
62.3133139173
–+113.7%+4.2%+24.6%
5.5211.7912.2815.50

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
1.41.41211.3
222355479872
83.178.1138150
11479.788.8141
4205147171,175
187232286452
29.152.597.1184
0.20.30.115
13.314.151.9115
191214282409
4205147171,175

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
48.465.748.769.6
−50−49.3−78.8−331
−9.8−12.752.7247
−11.43.722.7−14.1
−47.2−52.5−64.2−118
1.213.2−15.5−48.6

Shareholding pattern

Source: NSE filings
76.2%
promoters
  • Promoters76.15%
  • Public23.85%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202676.15%23.85%0.00
30 Jun 202676.15%23.85%0.00
31 Mar 202676.15%23.85%0.00
31 Dec 202576.15%23.85%0.00
27 Nov 202576.15%23.85%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you